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Primary tumors of the trachea can be benign or malignant. Benign tumors compose 10% of primary tumors and are usually misdiagnosed 
as asthma or chronic lung disease.1 Primary malignant 
tumors of the trachea are uncommon,2,3 accounting for 
0.1% to 0.4% of all malignancies.1 Squamous cell carci-
noma and adenoid cystic carcinoma are the most preva-
lent pathology.2 Primary presentation of extranodal 
lymphoma in trachea is rare.4 Previous studies in com-
bined data from 7 series of 425 cases of tracheal tumors 
(between 1930 and 1989), reported only 1 (0.23%) case 
with primary tracheal lymphoma (PTL).5-9 In a case 
series of primary tracheal tumors from Taiwan, lym-
phomas comprised 3% of the cohort10 and histologic 
subtype of anaplastic large cell lymphoma (ALCL) of 
the trachea was a rare finding.4 We describe a patient 
with PTL with an unusual presentation of subcutane-
ous emphysema that was treated with combined mo-
dality of debulking curettage, chemotherapy and local 
radiotherapy. 
CASE
A 16-year-old nonsmoking female with a 3-week his-
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Primary anaplastic large cell lymphoma of the trachea is a rare tumor. Common complaints are dyspnea 
and cough that could mimic a partially refractory asthma in some cases.  We report a 16-year-old female 
with an anaplastic large cell lymphoma (null cell type) in which tracheal involvement was presented with 
life-threatening airway obstruction and subcutaneous emphysema. After debulking the tumor by endo-
bronchial curettage, the patient was treated with chemotherapy followed by local radiotherapy. She had 
no evidence of local or distant recurrence after 25 months. Primary anaplastic large cell lymphoma of the 
trachea is a rare life-threatening disease. Nevertheless, this condition has a good prognosis if diagnosed 
immediately and treated with chemotherapy and radiotherapy.
tory of dry cough and progressive dyspnea, treated as 
asthma, abruptly developed subcutaneous emphysema 
in the neck and upper chest. The patient was subse-
quently transferred to our center for further manage-
ment. At the time of admission she had subcutaneous 
emphysema in the neck and upper chest and bilateral 
coarse crackles without peripheral lymphadenopathy or 
organomegaly.
In a primary work-up, chest computed tomogra-
phy (CT) showed a tracheal wall mass in the mid-tra-
chea (40 mm) that protruded into the lumen and led 
to severe stenosis. In the distal portion of the trachea 
the tumor invaded the lumen and air leakage was seen. 
Paratracheal lymphadenopathy was noted without 
adjacent vessels invasion. No lymphadenopathy was 
evident in other parts of mediastinum and pulmonary 
parenchyma was also clear on the CT scan. It also dem-
onstrated pneumomediastinum and bilateral axillary 
soft tissue emphysema (Figures 1a, 1b). Abdominal 
and pelvic CT scans were normal. Results of all blood 
tests including CBC and biochemistry, including LDH 
were within normal limits. 
By rigid bronchoscopy, a mass lesion protruding 
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from the posterior wall of the trachea 5-6 cm distal to 
the vocal cord was seen. The mass had occluded 5/6 of 
the luminal space, which was partially resected through 
a curettage procedure. Immediately after this procedure 
the dyspnea was resolved and she was admitted to ICU. 
Histopathological analysis of tumoral sections showed 
disintegrated fragments of neoplastic tissue, fibrinoleu-
kocytic exudates, necrosis and an ulcerated metaplastic 
bronchial epithelium. The neoplastic tissue was com-
posed of a proliferation of discohesive large anaplastic 
malignant cells associated with foci of delicate sclerosis. 
The sclerosis resulted in pseudocompartmentalization 
of the tumoral cells. The tumoral cells had large pleo-
morphic vesicular nucleolated nuclei. Numerous mi-
totic figures, as well as foci of necrosis, were also noted 
(Figure 2). Immunohistochemical study revealed that 
tumoral cells were diffusely and strongly positive for 
LCA and CD30 (membranous and cytoplasmic). Most 
of the tumoral cells showed both nuclei and cytoplasm 
positive for ALK staining. They were totally negative 
for pancytokeratin, α-fetoprotein, CD 20, CD79 and 
CD3. The Ki67 staining showed a high proliferation in-
dex. This finding confirmed the diagnosis of anaplastic 
large cell lymphoma, null cell type. 
Five days after first curettage she was transferred to 
the oncology ward in an ECOG performance status of 
2, but at the time of admission her dyspnea was aggra-
vated, which led to an urgent second bronchoscopy and 
curettage. Considering the patient’s critical situation, in 
the presence of normal CBC and plaletes and a localized 
disease, a bone marrow study was not performed. Finally, 
at stage IAE and low risk on the International Prognostic 
Index, 11 tracheal curettage was immediately followed by 
systemic chemotherapy with a CHOP regimen (cyclo-
phosphamide, doxorubicin, vincristine, and predniso-
lone) in ICU. She had a dramatic response to the first 
cycle of chemotherapy and in the following weeks, in 
observation, she did not develop any local progression. 
Her chemotherapy was continued for 6 cycles. Although, 
there was no evidence of residual tumor in the bronchos-
copy and chest CT scan, radiation over the bed of the 
tumor was performed. After 25 months on follow-up she 
was in complete remission without any evidence of tu-
mor recurrence in imaging and bronchoscopy.   
DISCUSSION
PTL originates from mesenchymal B and T cells prob-
ably involved in immunosurveillance of the upper air-
ways.1 In a large historical series of extranodal non-
Hodgkin lymphoma (NHL), only 3.6% presented with 
involvement of the pulmonary parenchyma or tracheo-
bronchial tree as the primary site of disease.12 Indeed 
even in a review of primary tracheal tumors from 
Taiwan, the prevalence of lymphoma was 3%.10 
Various histological subtypes of PTL exist. In 
a review of 28 cases of PTL, the most frequent sub-
type was mucosa-associated lymphoid tissue (MALT) 
lymphoma comprising 5 (18%) of all cases. Except for 
4 patients with unspecified T-cell lymphoma, the sec-
ond most common subtypes were Hodgkin disease and 
anaplastic large cell lymphoma (ALCL). Each of these 
subtypes was reported in 3 (11%) of the 28 patients.4 
ALCL is a rare high-grade and aggressive type of NHL 
including 2% to 3% of lymphomas.4,13-16 ALCL consists 
a distinctive anaplastic and polymorphous cell cytol-
Figure 1a,b. A right paratracheal mass infiltrating the tracheal lumen with subcutaneous 
emphysema.
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ogy13,14 characteristically expressed by one or more T-
cell-related antigens. Furthermore, in some of ALCL 
cases the loss of T-cell antigens may result in apparent 
null cell phenotype as showing T-cell linage at the mo-
lecular level.17 ALCL cells frequently spread into extra-
nodal regions such as skin, lung, pleura, pericardium, 
liver and ovary, especially in the T and null-cell pheno-
type.18 However T/null-cell type ALCL shows a favor-
able outcome, with 5-year survival reaching 81%19 as in 
our patient and the other reported cases of ALCL.4,20
In a review by Takami, 3 cases with a diagnosis of 
ALCL were aged between 20 to 60 years.4 Our case 
was a 16-year-old and another ALCL case was a 24-
year-old.20 Common presenting symptoms include 
dyspnea, cough, wheezing and at later stages, stridor.5 
Hemoptysis is not a common complaint. These com-
plaints could mimic a partially refractory asthma in some 
cases. Failure to respond to a bronchodilator should 
arise suspicion of a tracheal tumor.20 To the best of our 
knowledge this is the sole reported tracheal lymphoma 
presenting with subcutaneous emphysema beside pro-
gressive dyspnea. Although the history of complaints, 
Figure 2. On hematoxyline and eosin stain (×40), there are ratherly diffuse infiltration 
of highly anaplastic large lymphocytes with vesicular nucleolated nuclei, some with 
multilobulated nuclei and basophilic cytoplasm. There are also mixed population of 
PMNs and small lymphocytes as well as fine sclerosis (pseudocompartmentalization).
and a precise physical examination could raise the sus-
picion of a tracheal tumor, a CT scan can also demon-
strate a tracheal/paratracheal mass that may accompany 
local lymphadenopathies. However, for a definite diag-
nosis, bronchoscopy and biopsy is mandatory. Notably, 
early diagnosis could be life saving and mandate urgent 
diagnostic bronchoscopy and biopsy. Palliation of dys-
pnea could be achieved by curettage or stenting of the 
trachea. In PTL a high proliferation rate that is identi-
fied by high Ki-67 expression, can be a predictive value 
for a favorable response to chemotherapy and outcome. 
Treatment strategies for patients with primary tracheal 
lymphoma are controversial and may depend on pa-
thology subtype. Surgery, chemotherapy, and radiation 
therapy usually are used either alone or in combination. 
In our case the high proliferative rate indicated a very 
rapid progression following the first curettage proce-
dure and also a rapid dramatic response to the first che-
motherapy cycle. Although our patient received local 
radiation after complete response to chemotherapy, its 
role in this scenario is questionable. Commonly, radio-
therapy has been used in the postoperative setting or for 
palliative treatment of unresectable disease.3 PTL are 
usually sensitive to both chemotherapy and radiothera-
py and may be rapidly controlled by such modalities.7 It 
was recently suggested that temporary tracheal stenting 
followed by chemotherapy and/or radiotherapy is ben-
eficial in the management of tracheal lymphoma with 
symptomatic airways stenosis.7 Additionally, debulking 
surgery is likely to remain the mainstay of initial urgent 
treatment in cases of severe upper airway obstruction 
by an unknown tracheal tumor,4 as in our case, because 
this technique allows prompt diagnosis and reduce the 
risk of asphyxia, as well.
In conclusion, subcutaneous emphysema besides 
progressive dyspnea could be an alarming sign and symp-
tom of PTL. Lymphomatous involvement of the airway 
is a rare but frightening presentation of an eminently 
treatable condition and should be considered with a 
high index of suspicion in patients with dyspnea and 
wheeze unresponsive to bronchodilators. Meanwhile, 
in our case, an anaplastic large cell lymphoma-null cell 
type demonstrated a dramatic response to combination 
treatment modalities of debulking, chemotherapy and 
radiotherapy with a very good prognosis.
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